Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment

•The efficacy of axitnib is not affected by renal impairment.•Treatment outcomes including Objective response rate and Progression-free survival are were comparable among the five groups categorized according to renal function.•Among patients with an eGFR

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urologic oncology 2023-11, Vol.41 (11), p.458.e9-458.e19
Hauptverfasser:	Minami, Keita, Osawa, Takahiro, Kojima, Takahiro, Hara, Tomohiko, Eto, Masatoshi, Takeuchi, Ario, Nakai, Yasutomo, Ueda, Kosuke, Ozawa, Michinobu, Uemura, Motohide, Ohba, Kojiro, Tamura, Keita, Shindo, Tetsuya, Nakagomi, Hiroshi, Takahashi, Atsushi, Anai, Satoshi, Yokomizo, Akira, Morizane, Shuichi, Kimura, Takahiro, Shimazui, Toru, Miyauchi, Yasuyuki, Mitsuzuka, Koji, Hara, Hiroaki, Yoshimura, Koji, Shiina, Hiroaki, Ito, Youichi M, Murai, Sachiyo, Nishiyama, Hiroyuki, Shinohara, Nobuo, Kitamura, Hiroshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Axitinib Axitinib - therapeutic use Carcinoma, Renal Cell - pathology Cohort Studies Humans Indazoles - adverse effects Kidney Neoplasms - pathology Metastatic Renal cell carcinoma Renal impairment Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•The efficacy of axitnib is not affected by renal impairment.•Treatment outcomes including Objective response rate and Progression-free survival are were comparable among the five groups categorized according to renal function.•Among patients with an eGFR
ISSN:	1078-1439 1873-2496
DOI:	10.1016/j.urolonc.2023.08.008